Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspectiveNAUCK, M. A.Acta diabetologica (Print). 1998, Vol 35, Num 3, pp 117-129, issn 0940-5429Article

Is glucagon-like peptide 1 an incretin hormone?NAUCK, M. A.Diabetologia (Berlin). 1999, Vol 42, Num 3, pp 373-379, issn 0012-186XArticle

Polypharmacy in people with Type 1 and Type 2 diabetes is justified by current guidelines—a comprehensive assessment of drug prescriptions in patients needing inpatient treatment for diabetes-associated problemsBAUER, S; NAUCK, M. A.Diabetic medicine. 2014, Vol 31, Num 9, pp 1078-1085, issn 0742-3071, 8 p.Article

Six methods for the determination of C-peptide evaluatedNAUCK, M. S; NAUCK, M. A; NAUCK, M. A et al.NAUCK, M. A; NAUCK, M. A et al.Clinical chemistry and laboratory medicine. 1999, Vol 37, Num 7, pp 745-751, issn 1434-6621Article

Prolonged maximal stimulation of insulin secretion in healthy subjects does not provoke preferential release of proinsulinNAUCK, M. A; SIEGEL, E. G; CREUTZFELDT, W et al.Pancreas. 1991, Vol 6, Num 6, pp 645-652, issn 0885-3177Article

Proceedings from the GLP1 Meeting on the occasion of the 80th birthday of Prof. Dr. med. Dr. hc (em.) Werner CreutzfeldtSCHMIDT, W. E; NAUCK, M. A.Regulatory peptides. 2005, Vol 128, Num 2, issn 0167-0115, 83 p.Conference Proceedings

The [pre-] history of the incretin conceptCREUTZFELDT, Werner.Regulatory peptides. 2005, Vol 128, Num 2, pp 87-91, issn 0167-0115, 5 p.Conference Paper

Comparison of hyperinsulinaemic clamp experiments using venous, 'arterialized' venous or capillary euglycaemiaNAUCK, M. A; BLIETZ, R. W; QUALMANN, C et al.Clinical physiology (Oxford). 1996, Vol 16, Num 6, pp 589-602, issn 0144-5979Article

Hyperproinsulinemia in a three-generation caucasian family due to mutant proinsulin (Arg⁶⁵→His) not associated with impaired glucose tolerance : The contribution of mutant proinsulin to insulin bioactivityRØDER, M. E; VISSING, H; NAUCK, M. A et al.The Journal of clinical endocrinology and metabolism. 1996, Vol 81, Num 4, pp 1634-1640, issn 0021-972XArticle

Glycaemic effects of incretins in Type 1 diabetes mellitus A concise review, with emphasis on studies in humansDUPRE, John.Regulatory peptides. 2005, Vol 128, Num 2, pp 149-157, issn 0167-0115, 9 p.Conference Paper

The pathogenesis of NIDDM involves a defective expression of the GIP receptorHOLST, J. J; GROMADA, J; NAUCK, M. A et al.Diabetologia (Berlin). 1997, Vol 40, Num 8, pp 984-986, issn 0012-186XConference Paper

Sekundärer Diabetes bei gastroenterologischen Erkrankungen, Workshop anlässlich der 52. Tagung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten mit Sektion für Gastroenterologische EndoskopieHOPT, U. T; NAUCK, M. A.Zeitschrift für Gastroenterologie. 1999, issn 0044-2771, 42 p., SUP1Conference Proceedings

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?NAUCK, M. A; VARDARLI, I; DEACON, C. F et al.Diabetologia (Berlin). 2011, Vol 54, Num 1, pp 10-18, issn 0012-186X, 9 p.Article

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin : a non-inferiority studyNAUCK, M. A; DURAN, S; KIM, D et al.Diabetologia (Berlin). 2007, Vol 50, Num 2, pp 259-267, issn 0012-186X, 9 p.Article

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetesNAUCK, M. A; HOMPESCH, M; FILIPCZAK, R et al.Experimental and clinical endocrinology & diabetes. 2006, Vol 114, Num 8, pp 417-423, issn 0947-7349, 7 p.Article

What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?AHREN, B; NAUCK, M. A; EL-OUAGHLIDI, A et al.Diabetologia (Berlin). 2005, Vol 48, Num 4, pp 605-615, issn 0012-186X, 11 p.Article

α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patientsHÜCKING, K; KOSTIC, Z; POX, C et al.Diabetic medicine. 2005, Vol 22, Num 4, pp 470-476, issn 0742-3071, 7 p.Article

Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?MEIER, J. J; GALLWITZ, B; SCHMIDT, W. E et al.Heart (London 1996). 2004, Vol 90, Num 1, pp 9-12, issn 1355-6037, 4 p.Article

A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndromeNAUCK, M. A; MEIER, J. J; WOLFERSDORFF, A. V et al.Acta diabetologica (Print). 2003, Vol 40, Num 4, pp 163-172, issn 0940-5429, 10 p.Article

Does glucagon stimulation predict oral glucose tolerance in patients after simultaneous pancreas-kidney transplantationNAUCK, M. A; PFEFFER, F; ERB, M et al.Transplantation. 2000, Vol 70, Num 3, pp 545-547, issn 0041-1337Article

Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8FIESELER, P; BRIDENBAUGH, S; NUSTEDE, R et al.American journal of physiology. Endocrinology and metabolism. 1995, Vol 31, Num 5, pp E949-E955, issn 0193-1849Article

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy : a multicentre, randomised, double-blind, placebo-controlled studyNAUCK, M. A; ELLIS, G. C; FLECK, P. R et al.International journal of clinical practice (Esher). 2009, Vol 63, Num 1, pp 46-55, issn 1368-5031, 10 p.Article

Preserved GLP-1 effects in a diabetic patient with Cushing's diseaseRITZEL, R. A; KLEINE, N; HOIST, J. J et al.Experimental and clinical endocrinology & diabetes. 2007, Vol 115, Num 2, pp 146-150, issn 0947-7349, 5 p.Article

Combined pancreas and kidney transplantation in a lean Type 2 diabetic patient. Effects on insulin secretion and sensitivityPOX, C; RITZEL, R; BÜSING, M et al.Experimental and clinical endocrinology & diabetes. 2002, Vol 110, Num 8, pp 420-424, issn 0947-7349, 5 p.Article

FH-Freiburg: a novel missense mutation (C317Y) in growth factor repeat A of the low density lipoprotein receptor gene in a German patient with homozygous familial hypercholesterolemiaNAUCK, M. S; SCHARNAGL, H; NISSEN, H et al.Atherosclerosis. 2000, Vol 151, Num 2, pp 525-534, issn 0021-9150Article